Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03243721 · ClinicalTrials.gov registry record · NA
Gilenya's Impact on Cognitive Function and Thalamic Volumes
A NA study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT03243721 is a NA study that has completed, run by The Cleveland Clinic. The registered enrollment target is 20 participants.
The verdict
NCT03243721, a NA study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This evaluation will be a one-year feasibility study to characterize the neuroprotective benefits of Gilenya and its effects on cognition and grey matter volumes. The study will enroll 15 patients with relapsing-remitting multiple sclerosis being treated with Gilenya and 5 healthy controls. Each participant will undergo a battery of neurometric testing at baseline, six months, and one year. In addition, patients will undergo high-field 7T MRI at the same time points.
Interventions
- DIAGNOSTIC_TEST 7T MRI
- DIAGNOSTIC_TEST Neurocognitive testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-10-20 |
| Est. Completion | 2019-11-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03243721
The ClinicalTrials.gov registry entry for NCT03243721 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 7T MRI is the first listed.
NCT03243721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03243721 about?
NCT03243721 is a clinical study titled "Gilenya's Impact on Cognitive Function and Thalamic Volumes". This evaluation will be a one-year feasibility study to characterize the neuroprotective benefits of Gilenya and its effects on cognition and grey matter volumes. The study will enroll 15 patients with relapsing-remitting multiple sclerosis being treated with Gilenya and 5 healthy controls. Each par...
What is the current status of trial NCT03243721?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2017-10-20. Estimated completion is 2019-11-12.
What interventions are being tested in trial NCT03243721?
The interventions under investigation include: 7T MRI (DIAGNOSTIC_TEST), Neurocognitive testing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03243721?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.